Interferon lambda protects cattle against bovine viral diarrhea virus infection

• Published in: Veterinary immunology and immunopathology 2020-12, Vol.230, p.110145-110145, Article 110145
• Main Authors: Quintana, María Eugenia, Cardoso, Nancy Patricia, Pereyra, Rodrigo, Barone, Lucas José, Barrionuevo, Florencia Mariel, Mansilla, Florencia Celeste, Turco, Cecilia Soledad, Capozzo, Alejandra Victoria
• Format: Article
• Language: English
• Subjects: Antiviral therapy; Bovine viral diarrhea virus; Cattle; Type III interferon
• ISSN: 0165-2427; 1873-2534
• DOI: 10.1016/j.vetimm.2020.110145

Interferon lambda (IFN-λ) plays an important role in inducing an antiviral state in mucosal surfaces and has been used as an effective biotherapeutic against several viral diseases. Here we performed a proof of concept study on the activity of a biologically active recombinant bovine IFN-λ (rIFN-λ) produced in eukaryotic cells against Bovine Viral Diarrhea Virus (BVDV) in cattle. We first confirmed the lack of toxicity of different concentrations of rIFN-λ in bovine peripheral blood cells and the safety of its subcutaneous application in calves in doses up to 12 IU/kg. The antiviral activity of the rIFN-λ against BVDV was assessed in calves that were inoculated with 6 IU/kg of rIFN-λ (n = 4) or mock-treated (n = 2) two days before and after challenge with a BVDV type-2 non-cytopathic strain. Mock-treated animals developed respiratory disease, shedded the virus from 4 to 7 days post-infection (dpi) and had viremia between 4 and 14 dpi. Conversely, calves treated with rIFN-λ did not develop clinical symptoms. The virus was not found in nasal secretions or sera. Only one animal had a positive viral RNA detection in serum at 7 dpi. All infected animals treated with rIFN-λ increased systemic type-I IFNs levels at 4 dpi. The antiviral treatment induced an earlier onset of the anti-BVDV neutralizing antibodies. Altogether, these results constitute the proof-of-principle of bovine IFN-λ as an antiviral biotherapeutic to protect cattle against the clinical disease caused by BVDV.